Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women

Climacteric

Volumn 11, Issue 2, 2008, Pages 155-165

  Christodoulakos, G E ^a   Lambrinoudaki, I V ^a,b   Creatsa, M G ^a   Economou, E V ^a   Siasou, Z ^a   Panoulis, C P ^a   Kalligerou, I ^a   Papadias, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Adipocytokines; Apoptosis; Hormone Therapy; Postmenopause; Raloxifene; Tibolone

Indexed keywords

ADIPONECTIN; CONJUGATED ESTROGEN; ESTRADIOL; FAS LIGAND; NORETHISTERONE ACETATE; RALOXIFENE; RESISTIN; TIBOLONE;

ADULT; APOPTOSIS; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADIPOKINES; ADIPONECTIN; ADULT; ANTIGENS, CD95; APOPTOSIS; ATHEROSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FAS LIGAND PROTEIN; FEMALE; GREECE; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; RALOXIFENE; RESISTIN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 41349090401     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130801954484     Document Type: Article

References (45)

1. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. Ann NY Acad Sci 1990;592:193-203
2. Misso ML, Jang C, Adams J, et al. Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas 2005;51:299-306
3. Tanko LB, Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med 2005;258:544-53
4. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res 2005;126:121-9
5. Im JA, Lee JW, Lee HR, Lee DC. Plasma adiponectin levels in postmenopausal women with or without long-term hormone therapy. Maturitas 2006;54:65-71
6. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004;314:415-19
7. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9
8. Burnett MS, Lee CW, Kinnaird TD, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182:241-8
9. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006;91:64-8
10. Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM. Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost 2005;3:465-72
11. Amant C, Holm P, Xu S, Triman N, Kearney M, Losordo D. Estrogen receptor-mediated nitric oxide dependent modulation of the immunologic barrier function of the endometrium: regulation of Fas-ligand expression by estradiol. Circulation 2001;104:2576-81
12. van der Meer IM, Oei HH, Hofman A, Pols HA, de Jong FH, Witteman JC. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam Coronary Calcification Study. Atherosclerosis 2006;189:464-9
13. The Writing Group for the PEPI trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208
14. Clarkson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil 2002;47:61-8
15. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
16. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
17. The Writing Group for The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
18. Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects of symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002;5:60-9
19. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
20. Huang SW, Seow KM, Ho LT, et al. Resistin mRNA levels are down-regulated by estrogen in vivo and in vitro. FEBS Lett 2005;579:449-54
21. Sieminska L, Wojciechowska C, Niedziolka D, et al. Effect of postmenopause and hormone replacement therapy on serum adiponectin levels. Metabolism 2005;54:1610-14
22. Sumino H, Takahashi T, Idoh T, et al. Plasma adiponectin levels in postmenopausal women receiving hormone replacement therapy. J Int Med Res 2004;32:639-45
23. Milewicz A, Zatonska K, Demissie M, et al. Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol 2005;20:68-73
24. Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 2007;196:123.e1-7
25. Tan MH, Johns D, Glazer BN. Pioglitazone reduces atherogenic idex of plasma in patients with type 2 diabetes. Clin Chem 2004;50:1184-8
26. Christodoulakos GE, Lambrinoudaki IV, Economou EV, et al. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. J Cardiovasc Pharmacol 2006;47:542-8
27. Nickelsen T, Creatsas G, Rechberger T, et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 2001;4:320-31
28. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-19
29. Christodoulakos G, Lambrinoudaki I, Panoulis C, Rizos D, Coutoukos J, Creatsas G. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. Fertil Steril 2003;79:455-6
30. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-9
31. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003;88:2135-40
32. Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Economou E, Creatsas G. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. Fertil Steril 2004;82:634-8
33. Christodoulakos GE, Lambrinoudaki IV, Economou EV, et al. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. Atherosclerosis 2007;193:142-50
34. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-8
35. Mueck AO, Lippert C, Seeger H, Wallwiener D. Effects of tibolone on human breast cancer cells and human vascular coronary cells. Arch Gynecol Obstet 2003;267:139-44
36. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent anti-inflammatory properties. J Immunol 2005;174:5789-95
37. Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol 2005;32:839-44
38. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746-55
39. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest 1998;102:1682-9
40. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR. Human blood-derived macrophages induce apoptosis in human plaquederived vascular smooth muscle cells by Fas-ligand/Fas interactions. Atheroscler Thromb Vasc Biol 2001;21:1402-7
41. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007;27:168-74
42. Garcia-Moreno C, Catalan MP, Ortiz A, Alvarez L, De la Piedra C. Modulation of survival in osteoblasts from postmenopausal women. Bone 2004;35:170-7
43. Seli E, Guzeloglu-Kayisli O, Cakmak H, Kayisli UA, Selam B, Arici A. Estradiol increases apoptosis in human coronary artery endothelial cells (HCAEC) by up-regulating Fas and Fas ligand expression. J Clin Endocrinol Metab 2006;91:4995-5001
44. Shimizu M, Fukuo K, Nagata S, et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 2002;39:585-90
45. Okura T, Watanabe S, Jiang Y, et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002;20:895-910